newsfilter
← Latest News
GlobeNewswire·

Allena Pharmaceuticals Commences Dosing of Gout Patients in Second Phase 2a Trial of ALLN-346

- Fourteen-day study focused on high unmet need in patients with gout and chronic kidney disease - - Novel therapeutic candidate targets uric acid in the GI tract - - Initial data expected in late 2021 or early 2022 - NEWTON,